Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

The fate of many characters in Prime Target seems to depend on a dangerous mathematics equation, raising many questions about the show's realism.

VX-522: The multiple ascending dose (MAD) portion of the Phase 1/2 study of VX-522 is underway, with data expected in the first half of 2025. VX-522 is a CFTR mRNA therapeutic that Vertex is ...

Adding around $1.5 billion in annual sales by 2030 would be a step in the right direction for Vertex Pharmaceuticals but this wouldn't be a transformative contribution. In November, the company ...

Get Wall Street's Hottest Chart Every Morning RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients who ...

--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq ... autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

where the 2025 Formula 1 car’s minimum weight is more at 800kg. MEXICO CITY, MEXICO - JANUARY 10: Stoffel Vandoorne of Belgium driving the Maserati MSG Racing ... [+] Maserati Tipo Folgore ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO ... from myotonic dystrophy Type 1, autosomal dominant polycystic ...

Watch F1 races live on your phone & tablet with the Sky Sports app... with highlights, commentary, onboards and battle channel On the move? Not near a TV? Not in charge of the remote? How to watch ...